Variables

Type of drug (1L)

1L_age_start

1L_date_end

1L_date_start

Adverse Event (1L)

Did the AE affect 1L treatment: hold, discontinuation or dose reduction?

CTCAE grade of adverse event (1L)

AE outcome: resolved, persisted, or recurred after a certain period of time?

First line baseline LDH

1L_BOR

Specify regimen and e.g. if received within study (in text)

1L dose

1L frequency

1L drug unit

First line ECOG

1L Therapy on hold/discontinuation/dose reduction: none, onhold, discontinuation, or dose reduction

Sites of unresectable melanoma (1st line): Stage III: M1a, M1b, M1C, M1D

1L Progressive disease

1L Date PD

Type of 1L therapy

First line therapy?

Unresectable melanoma: date

1st Radiotherapy?

Date of start of 1st RT

Organ for first RT: Soft tissue: bone, lung, brain, other

Date of PD to 1st RT

PD in 1st RT site

1st RT Type: whole brain, SRS, SBRT, conventional

Type of drug (2L)

2L_age_start